What is Zacks Research’s Estimate for Chemours Q2 Earnings?

The Chemours Company (NYSE:CC) – Analysts at Zacks Research lowered their Q2 2025 earnings per share estimates for shares of Chemours in a note issued to investors on Monday, March 3rd. Zacks Research analyst R. Department now forecasts that the specialty chemicals company will post earnings of $0.58 per share for the quarter, down from their prior forecast of $0.71. The consensus estimate for Chemours’ current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours’ Q3 2025 earnings at $0.54 EPS, Q2 2026 earnings at $0.69 EPS, FY2026 earnings at $2.39 EPS and FY2027 earnings at $2.67 EPS.

A number of other research firms have also weighed in on CC. The Goldman Sachs Group reduced their target price on Chemours from $24.00 to $21.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Truist Financial began coverage on Chemours in a report on Tuesday, January 28th. They set a “buy” rating and a $27.00 price objective for the company. Morgan Stanley cut their price objective on Chemours from $25.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. BMO Capital Markets cut their price objective on Chemours from $34.00 to $27.00 and set an “outperform” rating for the company in a report on Wednesday, February 19th. Finally, Barclays cut their price objective on Chemours from $23.00 to $19.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $23.11.

Chemours Stock Up 5.3 %

CC stock opened at $14.12 on Wednesday. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The firm has a market capitalization of $2.11 billion, a PE ratio of 24.76 and a beta of 1.81. Chemours has a twelve month low of $13.31 and a twelve month high of $29.21. The stock has a 50-day simple moving average of $17.70 and a two-hundred day simple moving average of $18.76.

Chemours (NYSE:CC) last posted its earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. The business had revenue of $1.36 billion during the quarter, compared to analyst estimates of $1.37 billion. Chemours had a return on equity of 26.54% and a net margin of 1.51%.

Chemours Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Shareholders of record on Friday, February 28th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 7.08%. The ex-dividend date of this dividend is Friday, February 28th. Chemours’s payout ratio is currently 175.44%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Polar Asset Management Partners Inc. bought a new position in Chemours during the fourth quarter valued at approximately $2,392,000. iSAM Funds UK Ltd bought a new position in Chemours during the fourth quarter valued at approximately $332,000. Vision One Management Partners LP grew its position in Chemours by 12.1% during the fourth quarter. Vision One Management Partners LP now owns 1,558,498 shares of the specialty chemicals company’s stock valued at $26,339,000 after acquiring an additional 168,148 shares during the last quarter. Two Sigma Advisers LP grew its position in Chemours by 31.5% during the fourth quarter. Two Sigma Advisers LP now owns 661,500 shares of the specialty chemicals company’s stock valued at $11,179,000 after acquiring an additional 158,400 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in Chemours by 22.4% during the fourth quarter. Two Sigma Investments LP now owns 1,155,437 shares of the specialty chemicals company’s stock valued at $19,527,000 after acquiring an additional 211,641 shares during the last quarter. 76.26% of the stock is currently owned by institutional investors.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.